CDSCO Mandates Strict Independent Review for Unapproved Global Drugs

In a significant regulatory tightening, the Central Drugs Standard Control Organization issued a clear directive requiring comprehensive domestic evaluations for new drugs not yet approved globally. As per regulatory updates, all applications involving such pharmaceutical products must undergo rigorous assessment by the Investigational New Drug Division in New Delhi.

The mandate applies directly even when Phase III Global Clinical Trials involving Indian subjects are currently ongoing or have already been completed. This policy shift aims to reinforce independent domestic safety and efficacy scrutiny before novel therapeutics can be cleared for import and commercial marketing across India.

Pharmaceutical companies pursuing fast-tracked commercialization of novel molecules will now need to factor in extended evaluation timelines within the capital. Stakeholders anticipate that this heightened regulatory oversight will prioritize patient safety while reshaping approval pathways for global drug developers entering the Indian market.